Shockwave Medical, Inc. SWAV
We take great care to ensure that the data presented and summarized in this overview for Shockwave Medical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SWAV
View all-
Black Rock Inc. New York, NY3.78MShares$1.27 Billion0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.64MShares$1.22 Billion0.02% of portfolio
-
Wellington Management Group LLP Boston, MA2.61MShares$874 Million0.15% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI1.53MShares$512 Million0.77% of portfolio
-
State Street Corp Boston, MA1.09MShares$365 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY1.09MShares$364 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA627KShares$210 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD598KShares$200 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA585KShares$196 Million0.03% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY524KShares$175 Million2.21% of portfolio
Latest Institutional Activity in SWAV
Top Purchases
Top Sells
About SWAV
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Insider Transactions at SWAV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 31
2024
|
Antoine Papiernik Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
736
-100.0%
|
-
|
|
May 31
2024
|
Antoine Papiernik Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
34,177
-100.0%
|
-
|
|
May 31
2024
|
Frederic H Moll Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
287,521
-100.0%
|
-
|
|
May 31
2024
|
Laura Francis Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,551
-100.0%
|
-
|
|
May 31
2024
|
Laura Francis Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,233
-100.0%
|
-
|
|
May 31
2024
|
Frank T Watkins Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,532
-100.0%
|
-
|
|
May 31
2024
|
Sara Toyloy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,673
-100.0%
|
-
|
|
May 31
2024
|
Maria Sainz Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,328
-100.0%
|
-
|
|
May 31
2024
|
Trinh Phung SVP, Finance |
SELL
Sale (or disposition) back to the issuer
|
Direct |
50,387
-100.0%
|
-
|
|
May 31
2024
|
Douglas Evan Godshall President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
151,629
-100.0%
|
-
|
|
May 31
2024
|
Isaac Zacharias President, CCO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
56,288
-100.0%
|
-
|
|
May 31
2024
|
Renee Gaeta Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,890
-100.0%
|
-
|
|
May 31
2024
|
Kevin J. Ballinger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,733
-100.0%
|
-
|
|
May 31
2024
|
C Raymond Larkin Jr Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,281
-100.0%
|
-
|
|
May 22
2024
|
Trinh Phung SVP, Finance |
SELL
Bona fide gift
|
Direct |
100
-0.2%
|
-
|
|
May 17
2024
|
Trinh Phung SVP, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
19,763
+11.53%
|
$79,052
$4.72 P/Share
|
|
May 02
2024
|
Isaac Zacharias President, CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
530
-0.47%
|
$174,370
$329.81 P/Share
|
|
May 02
2024
|
Trinh Phung SVP, Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
328
-0.53%
|
$107,912
$329.81 P/Share
|
|
May 02
2024
|
Douglas Evan Godshall President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,144
-0.38%
|
$376,376
$329.81 P/Share
|
|
Mar 26
2024
|
Isaac Zacharias President, CCO |
SELL
Open market or private sale
|
Direct |
4,000
-6.58%
|
$1,148,000
$287.67 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 97K shares |
|---|---|
| Exercise of conversion of derivative security | 247K shares |
| Bona fide gift | 3K shares |
| Payment of exercise price or tax liability | 55.5K shares |
|---|---|
| Open market or private sale | 206K shares |
| Sale (or disposition) back to the issuer | 626K shares |
| Bona fide gift | 3.1K shares |
| Other acquisition or disposition | 21.9K shares |